BiotechTube
Home/Galderma Group/Andrew McConaghie
AM

Andrew McConaghie

Chief Financial Officer

Galderma Group

Therapeutic Areas

DermatologyAesthetic Medicine

Galderma Group Pipeline

DrugIndicationPhase
NemolizumabModerate-to-Severe Atopic Dermatitis (Adults/Adolescents)Approved/Filed
RelabotulinumtoxinA (QM1114)Aesthetic IndicationsPhase 3
Bimatoprost Sustained-ReleaseGlaucoma/Ocular HypertensionPhase 3
CD07805/47Inflammatory Dermatoses (e.g., Psoriasis)Phase 2
GM-502Androgenetic AlopeciaPhase 2
GM-503Acne VulgarisPhase 1

Leadership Team at Galderma Group

FØ
Flemming Ørnskov
Chief Executive Officer
BS
Baldo Scassellati Sforzolini
Global Head of Research & Development
BF
Brett Feinstein
Chief Commercial Officer
HL
Hervé Lilliu
Chairman of the Board
View full Galderma Group profile